Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care

The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort

(2014) Manuel F Ugarte-Gil et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)

(2014) David Isenberg et al.   ANNALS OF THE RHEUMATIC DISEASES

Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort

(2014) Ian N Bruce et al.   ANNALS OF THE RHEUMATIC DISEASES

Mediators of Inflammation and Their Effect on Resident Renal Cells: Implications in Lupus Nephritis

(2013) Susan Yung et al.   Clinical & Developmental Immunology

Disease Control and Safety of Belimumab Plus Standard Therapy Over 7 Years in Patients with Systemic Lupus Erythematosus

(2013) E. M. Ginzler et al.   JOURNAL OF RHEUMATOLOGY

Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up

(2013) Daniel J. Wallace et al.   RHEUMATOLOGY

The Systemic Lupus International Collaborating Clinics (SLICC) damage index: A systematic literature review

(2013) Emily J. Sutton et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus

(2012) DJ Wallace et al.   LUPUS

Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE

(2012) MA Dooley et al.   LUPUS

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

(2011) Richard Furie et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

(2011) Sandra V Navarra et al.   LANCET

Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort

(2011) R. Lopez et al.   RHEUMATOLOGY

Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus

(2010) J. Nossent et al.   LUPUS

Initial and accrued damage as predictors of mortality in Brazilian patients with systemic lupus erythematosus: a cohort study

(2008) CRL Cardoso et al.   LUPUS

Systemic Lupus Erythematosus

(2008) Anisur Rahman et al.   NEW ENGLAND JOURNAL OF MEDICINE